# EDWARDS LIFESCIENCES CORPORATION (EW) FY2024 Q3 P&L / Income Statement

- Company: EDWARDS LIFESCIENCES CORPORATION (EW)
- Period: 2024-07-01 to 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-11-06, accession number 0001099800-24-000086
- Page: https://plicit.ai/financials/ew/fy2024-q3-income-statement
- Chart image: https://plicit.ai/charts/ew-fy2024-q3-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2024-07-01 through 2024-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 1,354,400,000 US dollars
- **Cost of sales**: 262,900,000 US dollars
- **Gross profit**: 1,091,500,000 US dollars
- **Operating costs, including other operating expenses (calculated)**: 740,900,000 US dollars
- **Operating income, net**: 350,600,000 US dollars
- **Other income (expense), net (calculated)**: 52,200,000 US dollars
- **Income from continuing operations before provision for income taxes**: 402,800,000 US dollars
- **Provision for income taxes**: 40,700,000 US dollars
- **Net income**: 3,069,400,000 US dollars
- **Transcatheter Aortic Valve Replacement**: 1,023,300,000 US dollars
- **Transcatheter Mitral and Tricuspid Therapies**: 91,100,000 US dollars
- **Surgical Structural Heart**: 240,000,000 US dollars
- **Selling, general, and administrative expenses**: 421,400,000 US dollars
- **Research and development expenses**: 253,400,000 US dollars
- **Intellectual property agreement and certain litigation expenses (Note 3)**: 10,800,000 US dollars
- **Change in fair value of contingent consideration liabilities (Note 9)**: 0 US dollars
- **Restructuring expenses (Note 4)**: 32,900,000 US dollars
- **Other operating expenses, net**: 22,400,000 US dollars
- **Income from discontinued operations, net of tax**: 2,707,300,000 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
- Of which attributable to EDWARDS LIFESCIENCES CORPORATION: $3.07 B; to noncontrolling interests: −$1.40 M.

## Chart details: Revenue by Business Segment

- Page: https://plicit.ai/financials/ew/fy2024-q3-income-statement/revenue-by-business-segment
- Chart image: https://plicit.ai/charts/ew-fy2024-q3-revenue-by-business-segment-sankey.png

Income statement for 2024-07-01 through 2024-09-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 1,354,400,000 US dollars
- **Cost of sales**: 262,900,000 US dollars
- **Gross profit**: 1,091,500,000 US dollars
- **Operating costs, including other operating expenses (calculated)**: 740,900,000 US dollars
- **Operating income, net**: 350,600,000 US dollars
- **Other income (expense), net (calculated)**: 52,200,000 US dollars
- **Income from continuing operations before provision for income taxes**: 402,800,000 US dollars
- **Provision for income taxes**: 40,700,000 US dollars
- **Net income**: 3,069,400,000 US dollars
- **United States**: 804,600,000 US dollars
- **Europe**: 315,100,000 US dollars
- **Japan**: 85,800,000 US dollars
- **Rest of World**: 153,200,000 US dollars
- **Selling, general, and administrative expenses**: 421,400,000 US dollars
- **Research and development expenses**: 253,400,000 US dollars
- **Intellectual property agreement and certain litigation expenses (Note 3)**: 10,800,000 US dollars
- **Change in fair value of contingent consideration liabilities (Note 9)**: 0 US dollars
- **Restructuring expenses (Note 4)**: 32,900,000 US dollars
- **Other operating expenses, net**: 22,400,000 US dollars
- **Revenue before reconciliation (calculated)**: 1,358,700,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Reconciling items**: negative 4,300,000 US dollars. Reported reconciliation to consolidated revenue.
- **Income from discontinued operations, net of tax**: 2,707,300,000 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
- Of which attributable to EDWARDS LIFESCIENCES CORPORATION: $3.07 B; to noncontrolling interests: −$1.40 M.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/ew/fy2024-q3-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/ew-fy2024-q3-revenue-by-geography-sankey.png

Income statement for 2024-07-01 through 2024-09-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 1,354,400,000 US dollars
- **Cost of sales**: 262,900,000 US dollars
- **Gross profit**: 1,091,500,000 US dollars
- **Operating costs, including other operating expenses (calculated)**: 740,900,000 US dollars
- **Operating income, net**: 350,600,000 US dollars
- **Other income (expense), net (calculated)**: 52,200,000 US dollars
- **Income from continuing operations before provision for income taxes**: 402,800,000 US dollars
- **Provision for income taxes**: 40,700,000 US dollars
- **Net income**: 3,069,400,000 US dollars
- **UNITED STATES**: 804,600,000 US dollars
- **Europe**: 319,800,000 US dollars
- **JAPAN**: 81,400,000 US dollars
- **Rest of World**: 148,600,000 US dollars
- **Selling, general, and administrative expenses**: 421,400,000 US dollars
- **Research and development expenses**: 253,400,000 US dollars
- **Intellectual property agreement and certain litigation expenses (Note 3)**: 10,800,000 US dollars
- **Change in fair value of contingent consideration liabilities (Note 9)**: 0 US dollars
- **Restructuring expenses (Note 4)**: 32,900,000 US dollars
- **Other operating expenses, net**: 22,400,000 US dollars
- **Income from discontinued operations, net of tax**: 2,707,300,000 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
- Of which attributable to EDWARDS LIFESCIENCES CORPORATION: $3.07 B; to noncontrolling interests: −$1.40 M.